China’s Biotech Revolution

The podcast, hosted by Jack Lin from Morgan Stanley's China healthcare team, discusses the significant growth and global impact of China's biotech sector. Lin highlights that China is transitioning from generics manufacturing to a major player in global innovation, projecting that China-originated assets could account for a third of U.S. FDA approvals by 2040, up from 5% currently. This transformation is attributed to lower costs, improved accessibility through streamlined regulatory pathways, and increasing innovation quality. Despite geopolitical tensions, the podcast anticipates a future of "coopetition" (competition and collaboration) as global pharma balances innovation and resilience, emphasizing the need for stakeholders worldwide to adapt their strategies in response to this evolving landscape.